オンダンセトロン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "オンダンセトロン" in Japanese language version.

refsWebsite

Global rank Japanese rank

22nih.gov

4^th place

24^th place

15doi.org

2^nd place

6^th place

6pmda.go.jp

6,690^th place

394^th place

2google.ca

838^th place

1,403^rd place

2fda.gov

447^th place

1,043^rd place

1drugs.com

399^th place

1,603^rd place

1anesth.or.jp

low place

1who.int

195^th place

376^th place

1maruishi-pharm.co.jp

low place

1uptodate.com

3,771^st place

low place

1worldcat.org

5^th place

19^th place

1shouman.jp

low place

1medicallibrary-dsc.info

low place

1sawai.co.jp

low place

1bmj.com

1,226^th place

1,988^th place

1jamanetwork.com

2,650^th place

3,384^th place

1wikipedia.org

low place

1psychiatryonline.org

4,032^nd place

6,830^th place

1factsandcomparisons.com

low place

anesth.or.jp

“【周知】オンダンセトロンとグラニセトロン「術後悪心嘔吐」の保険適用について（更新）｜公益社団法人日本麻酔科学会”. anesth.or.jp. 2023年10月13日閲覧。

bmj.com

Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ (September 1997). “Impact of covert duplicate publication on meta-analysis: a case study”. BMJ 315 (7109): 635–40. doi:10.1136/bmj.315.7109.635. PMC 2127450. PMID 9310564.

doi.org

Schnadower, D; Finkelstein, Y; Freedman, SB (January 2015). “Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries.”. Current opinion in gastroenterology 31 (1): 1–6. doi:10.1097/mog.0000000000000132. PMID 25333367.
Freedman, SB; Ali, S; Oleszczuk, M; Gouin, S; Hartling, L (July 2013). “Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries.”. Evidence-based child health : a Cochrane review journal 8 (4): 1123–37. doi:10.1002/ebch.1932. PMID 23877938.
Pasternak B, Svanström H, Hviid A (February 2013). “Ondansetron in pregnancy and risk of adverse fetal outcomes”. N. Engl. J. Med. 368 (9): 814–23. doi:10.1056/NEJMoa1211035. PMID 23445092.
Koren, G (December 2014). “Treating morning sickness in the United States--changes in prescribing are needed”. American Journal of Obstetrics and Gynecology 211 (6): 602–6. doi:10.1016/j.ajog.2014.08.017. PMID 25151184.
Danielsson, Bengt; Wikner, Birgitta Norstedt; Källén, Bengt (2014-12-01). “Use of ondansetron during pregnancy and congenital malformations in the infant”. Reproductive Toxicology (Elmsford, N.Y.) 50: 134–137. doi:10.1016/j.reprotox.2014.10.017. ISSN 1873-1708. PMID 25450422.
Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, Hasler WL, Hyman PE, Issenman RM, Li BU, Linder SL, Mayer EA, McCallum RW, Olden K, Parkman HP, Rudolph CD, Taché Y, Tarbell S, Vakil N (April 2008). “Cyclic vomiting syndrome in adults”. Neurogastroenterol. Motil. 20 (4): 269–84. doi:10.1111/j.1365-2982.2008.01113.x. PMID 18371009.
Freedman SB, Adler M, Seshadri R, Powell EC (April 2006). “Oral ondansetron for gastroenteritis in a pediatric emergency department”. N. Engl. J. Med. 354 (16): 1698–705. doi:10.1056/NEJMoa055119. PMID 16625009.
Sturm JJ, Hirsh DA, Schweickert A, Massey R, Simon HK (May 2010). “Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?”. Ann Emerg Med 55 (5): 415–22. doi:10.1016/j.annemergmed.2009.11.011. PMID 20031265.
Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ (September 1997). “Impact of covert duplicate publication on meta-analysis: a case study”. BMJ 315 (7109): 635–40. doi:10.1136/bmj.315.7109.635. PMC 2127450. PMID 9310564.
Rennie D (November 1999). “Fair conduct and fair reporting of clinical trials”. JAMA 282 (18): 1766–8. doi:10.1001/jama.282.18.1766. PMID 10568651.
Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ (2006). “Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study”. Schizophrenia Research（英語版） 88 (1–3): 102–10. doi:10.1016/j.schres.2006.07.010. PMID 16959472.
Zullino DF, Eap CB, Voirol P (2001). “Ondansetron for tardive dyskinesia”. Am J Psychiatry 158 (4): 657–8. doi:10.1176/appi.ajp.158.4.657-a. PMID 11282718.
Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD (February 2000). “Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia”. Am J Psychiatry 157 (2): 287–9. doi:10.1176/appi.ajp.157.2.287. PMID 10671405.
Zoldan J, Friedberg G, Livneh M, Melamed E (1995). “Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist”. Neurology 45 (7): 1305–8. doi:10.1212/WNL.45.7.1305. PMID 7617188.
Generali JA, Cada DJ (August 2009). “Ondansetron: postanesthetic shivering”. Hospital Pharmacy 44 (8): 670–1. doi:10.1310/hpj4408-670.

drugs.com

“Ondansetron Hydrochloride”. The American Society of Health-System Pharmacists. Jan 2016閲覧。

factsandcomparisons.com

Generali JA, Cada DJ (August 2009). “Ondansetron: postanesthetic shivering”. Hospital Pharmacy 44 (8): 670–1. doi:10.1310/hpj4408-670.

fda.gov

accessdata.fda.gov

GlaxoSmithKline. “Zofran” (PDF). Prescribing Information. U.S. Food and Drug Administration. 2016年5月18日閲覧。

fda.gov

US Food and Drug Administration. (2012). FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm

google.ca

books.google.ca

Miloro, ed. by Michael (2012). Peterson's principles of oral and maxillofacial surgery. (3rd ed.). Shelton, CT: People's Medical Pub. House-USA. p. 86. ISBN 9781607951117
Sneader, Walter (2005). Drug discovery : a history (Rev. and updated ed.). Chichester: Wiley. p. 217. ISBN 9780471899792

jamanetwork.com

jama.jamanetwork.com

Rennie D (November 1999). “Fair conduct and fair reporting of clinical trials”. JAMA 282 (18): 1766–8. doi:10.1001/jama.282.18.1766. PMID 10568651.

maruishi-pharm.co.jp

槇田浩史. “実践麻酔シリーズ PONV対策と麻酔” (PDF). p. 21. 2016年5月18日閲覧。

medicallibrary-dsc.info

“添付文書に聴く（3）「適宜増減」「適宜減量」「適宜増量」” (PDF). 2016年5月19日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Schnadower, D; Finkelstein, Y; Freedman, SB (January 2015). “Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries.”. Current opinion in gastroenterology 31 (1): 1–6. doi:10.1097/mog.0000000000000132. PMID 25333367.
Freedman, SB; Ali, S; Oleszczuk, M; Gouin, S; Hartling, L (July 2013). “Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries.”. Evidence-based child health : a Cochrane review journal 8 (4): 1123–37. doi:10.1002/ebch.1932. PMID 23877938.
Sutton, M; Mounsey, AL; Russell, RG (15 July 2012). “FPIN's Clinical Inquiries. Treatment of motion sickness.”. American family physician 86 (2): 192–5. PMID 22962932.
Cooke, C. E.; Mehra, I. V. (1994). “Oral ondansetron for preventing nausea and vomiting”. American journal of hospital pharmacy 51 (6): 762–771. PMID 8010314.
Pasternak B, Svanström H, Hviid A (February 2013). “Ondansetron in pregnancy and risk of adverse fetal outcomes”. N. Engl. J. Med. 368 (9): 814–23. doi:10.1056/NEJMoa1211035. PMID 23445092.
Koren, G (December 2014). “Treating morning sickness in the United States--changes in prescribing are needed”. American Journal of Obstetrics and Gynecology 211 (6): 602–6. doi:10.1016/j.ajog.2014.08.017. PMID 25151184.
Danielsson, Bengt; Wikner, Birgitta Norstedt; Källén, Bengt (2014-12-01). “Use of ondansetron during pregnancy and congenital malformations in the infant”. Reproductive Toxicology (Elmsford, N.Y.) 50: 134–137. doi:10.1016/j.reprotox.2014.10.017. ISSN 1873-1708. PMID 25450422.
Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, Hasler WL, Hyman PE, Issenman RM, Li BU, Linder SL, Mayer EA, McCallum RW, Olden K, Parkman HP, Rudolph CD, Taché Y, Tarbell S, Vakil N (April 2008). “Cyclic vomiting syndrome in adults”. Neurogastroenterol. Motil. 20 (4): 269–84. doi:10.1111/j.1365-2982.2008.01113.x. PMID 18371009.
Freedman SB, Adler M, Seshadri R, Powell EC (April 2006). “Oral ondansetron for gastroenteritis in a pediatric emergency department”. N. Engl. J. Med. 354 (16): 1698–705. doi:10.1056/NEJMoa055119. PMID 16625009.
Sturm JJ, Hirsh DA, Schweickert A, Massey R, Simon HK (May 2010). “Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?”. Ann Emerg Med 55 (5): 415–22. doi:10.1016/j.annemergmed.2009.11.011. PMID 20031265.
Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ (September 1997). “Impact of covert duplicate publication on meta-analysis: a case study”. BMJ 315 (7109): 635–40. doi:10.1136/bmj.315.7109.635. PMC 2127450. PMID 9310564.
Rennie D (November 1999). “Fair conduct and fair reporting of clinical trials”. JAMA 282 (18): 1766–8. doi:10.1001/jama.282.18.1766. PMID 10568651.
Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ (2006). “Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study”. Schizophrenia Research（英語版） 88 (1–3): 102–10. doi:10.1016/j.schres.2006.07.010. PMID 16959472.
Zullino DF, Eap CB, Voirol P (2001). “Ondansetron for tardive dyskinesia”. Am J Psychiatry 158 (4): 657–8. doi:10.1176/appi.ajp.158.4.657-a. PMID 11282718.
Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD (February 2000). “Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia”. Am J Psychiatry 157 (2): 287–9. doi:10.1176/appi.ajp.157.2.287. PMID 10671405.
Zoldan J, Friedberg G, Livneh M, Melamed E (1995). “Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist”. Neurology 45 (7): 1305–8. doi:10.1212/WNL.45.7.1305. PMID 7617188.
Miller, PM; Book, SW; Stewart, SH (2011). “Medical treatment of alcohol dependence: a systematic review.”. International journal of psychiatry in medicine 42 (3): 227-66. PMID 22439295.
Lee, TH; Szabo, ST; Fowler, JC; Mannelli, P; Mangum, OB; Beyer, WF; Patkar, A; Wetsel, WC (1 July 2012). “Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.”. Drug and alcohol dependence 124 (1-2): 11-8. PMID 22356892.

pubchem.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ (September 1997). “Impact of covert duplicate publication on meta-analysis: a case study”. BMJ 315 (7109): 635–40. doi:10.1136/bmj.315.7109.635. PMC 2127450. PMID 9310564.

pmda.go.jp

info.pmda.go.jp

“ゾフラン錠2／ゾフラン錠4 添付文書” (2016年4月). 2016年5月18日閲覧。
“ゾフラン錠小児用シロップ0.05% 添付文書” (2016年4月). 2016年5月18日閲覧。
“ゾフランザイディス4 添付文書” (2016年4月). 2016年5月18日閲覧。
“ゾフラン注2／ゾフラン注4 添付文書” (2016年4月). 2016年5月18日閲覧。
“ゾフラン錠2／錠4／小児用シロップ0.05% インタビューフォーム” (PDF) (2016年4月). 2016年5月19日閲覧。
“ゾフラン注2／注4 インタビューフォーム” (PDF) (2016年4月). 2016年5月19日閲覧。

psychiatryonline.org

ajp.psychiatryonline.org

Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD (February 2000). “Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia”. Am J Psychiatry 157 (2): 287–9. doi:10.1176/appi.ajp.157.2.287. PMID 10671405.

sawai.co.jp

med.sawai.co.jp

『オンダンセトロン注射液、インタビューフォーム（改訂第2版）』 p.15 2012年3月

shouman.jp

“周期性嘔吐症候群概要”. 小児慢性特定疾病情報センター (2014年10月1日). 2016年5月19日閲覧。

uptodate.com

Smith JA, Refuerzo JS, Ramin SM. “Treatment and outcome of nausea and vomiting of pregnancy”. UpToDate. 2016年5月18日閲覧。

who.int

“19th WHO Model List of Essential Medicines (April 2015)”. WHO (April 2015). May 10, 2015閲覧。

wikipedia.org

en.wikipedia.org

Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ (2006). “Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study”. Schizophrenia Research（英語版） 88 (1–3): 102–10. doi:10.1016/j.schres.2006.07.010. PMID 16959472.

worldcat.org

search.worldcat.org

Danielsson, Bengt; Wikner, Birgitta Norstedt; Källén, Bengt (2014-12-01). “Use of ondansetron during pregnancy and congenital malformations in the infant”. Reproductive Toxicology (Elmsford, N.Y.) 50: 134–137. doi:10.1016/j.reprotox.2014.10.017. ISSN 1873-1708. PMID 25450422.